Get started
Author

Lina Y. Dimberg

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
2012 · L Y Dimberg, C K Anderson, et al. · Oncogene · 276
The Hepatitis C Virus Core Protein Modulates T Cell Responses by Inducing Spontaneous and Altering T-cell Receptor-triggered Ca2+ Oscillations
2003 · Anders Bergqvist, Sara Sundström, et al. · Journal of Biological Chemistry · 61
Hepatitis C Virus Core Protein Induces an Anergic State Characterized by Decreased Interleukin-2 Production and Perturbation of Mitogen-Activated Protein Kinase Responses
2005 · Sara Sundström, Seisuke Ota, et al. · Journal of Virology · 28
Retinoic Acid Inhibits in vitro Development of Mast Cells But Has No Marked Effect on Mature Human Skin Tryptase- and Chymase-Positive Mast Cells
2003 · Malin Hjertson, Lina Dimberg, et al. · Journal of Investigative Dermatology · 27
PDF
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells
2005 · Lina Y. Dimberg, Anna I. Dimberg, et al. · Blood · 26
PDF
Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
2012 · Lina Y Dimberg, Anna Dimberg, et al. · BMC Cancer · 24
PDF
A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2017 · Lina Y. Dimberg, Christina G. Towers, et al. · Molecular Cancer Research · 16
Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells
2016 · Jacqueline Thorburn, Leah Staskiewicz, et al. · Molecular Pharmacology · 12
PDF
Red Blood Cells Derived from Whole Blood Treated with Riboflavin and UV Light Maintain Adequate Cell Quality through 21 Days of Storage
2019 · Lina Y. Dimberg, Suzann K. Doane, et al. · Transfusion Medicine and Hemotherapy · 9
PDF
Abstract PS13-09: Chemotherapy-induced nausea and vomiting (CINV) risk after prior breakthrough CINV: Unmasking the false average
2021 · Rudolph M Navari, Gary Binder, et al. · Cancer Research · 2
Pathogen Reduction Technologies
2018 · Susanne Marschner, Lina Y. Dimberg · Elsevier eBooks · 2
Supplementary Table 3 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplemental Table 1 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplemental Legends from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplementary Figures 1-5 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplemental Table 2 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplementary Table 3 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Data from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplemental Legends from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplemental Table 1 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplemental Table 2 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Supplementary Figures 1-5 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
Data from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance
2023 · Lina Y. Dimberg, Christina G. Towers, et al.
List of Contributors
2018 · Suchitra S. Acharya, Judith Aeschlimann, et al. · Elsevier eBooks
Abstract B115: Use of a genome-wide loss-of-function screen to identify novel mechanisms of resistance to TRAIL induced apoptosis.
2013 · Lina Y. Dimberg, Joshua Cabrera, et al. · Molecular Cancer Therapeutics
Works count: 31
Citation count: 483
H-index: 9
I10-index: 8
Year
Topic
Type